Soticlestat in Dravet Syndrome or Lennox-Gastaut Syndrome Exposed to Fenfluramine

Phase 3, open-label, single-arm trial of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome (LGS), sponsored by Takeda. Primary endpoints: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days at 12 weeks and Percent Change From Baseline in Major Motor Drop (MMD) Seizure Frequency Per 28 Days at 12 weeks. Started Apr 2024; status: terminated.